Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
PAVESE, IDA
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma	Completed	2	106	Europe	Onivyde, no other intervention name to add, Paclitaxel	Federation Francophone de Cancerologie Digestive, Shire, Servier	Squamous Cell Carcinoma	04/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
PAVESE, IDA
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma	Completed	2	106	Europe	Onivyde, no other intervention name to add, Paclitaxel	Federation Francophone de Cancerologie Digestive, Shire, Servier	Squamous Cell Carcinoma	04/24	09/24